454 related articles for article (PubMed ID: 28300676)
1. Bare Metal Versus Paclitaxel-Eluting Stents for Long Femoropopliteal Lesions: Prospective Cohorts Comparison Using a Propensity Score-Matched Analysis.
Vent PA; Kaladji A; Davaine JM; Guyomarch B; Chaillou P; Costargent A; Quillard T; Gouëffic Y
Ann Vasc Surg; 2017 Aug; 43():166-175. PubMed ID: 28300676
[TBL] [Abstract][Full Text] [Related]
2. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
[TBL] [Abstract][Full Text] [Related]
3. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Tran K; Ullery BW; Kret MR; Lee JT
Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
[TBL] [Abstract][Full Text] [Related]
4. A single center experience of Zilver PTX for femoro-popliteal lesions.
Kang WY; Campia U; Didier RJ; Kiramijyan S; Koifman E; Negi SI; Lipinski MJ; Baker NC; Escarcega RO; Torguson R; Waksman R; Bernardo NL
Cardiovasc Revasc Med; 2016 Sep; 17(6):399-403. PubMed ID: 27496591
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
[TBL] [Abstract][Full Text] [Related]
7. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
Zeller T; Dake MD; Tepe G; Brechtel K; Noory E; Beschorner U; Kultgen PL; Rastan A
JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
[TBL] [Abstract][Full Text] [Related]
8. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
[TBL] [Abstract][Full Text] [Related]
9. Increased mortality with paclitaxel-eluting stents is driven by lesion length.
Mathlouthi A; Yei KS; Naazie I; Bertges DJ; Malas MB
J Vasc Surg; 2021 Feb; 73(2):548-553.e2. PubMed ID: 32615286
[TBL] [Abstract][Full Text] [Related]
10. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
[TBL] [Abstract][Full Text] [Related]
11. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Endovascular Versus Bypass Surgery in Femoropopliteal TASC II D Lesions: A Single-Center Study.
Veraldi GF; Mezzetto L; Macrì M; Criscenti P; Corvasce A; Poli R
Ann Vasc Surg; 2018 Feb; 47():179-187. PubMed ID: 28943491
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T
J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
[TBL] [Abstract][Full Text] [Related]
14. 1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty.
Bisdas T; Beropoulis E; Argyriou A; Torsello G; Stavroulakis K
JACC Cardiovasc Interv; 2018 May; 11(10):957-966. PubMed ID: 29798772
[TBL] [Abstract][Full Text] [Related]
15. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
[TBL] [Abstract][Full Text] [Related]
16. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease.
Fujihara M; Utsunomiya M; Higashimori A; Yokoi Y; Nakamura M
Heart Vessels; 2016 Feb; 31(2):152-7. PubMed ID: 25351136
[TBL] [Abstract][Full Text] [Related]
18. Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
Phair J; Carnevale M; Lipsitz EC; Shariff S; Scher L; Garg K
Ann Vasc Surg; 2020 Jul; 66():595-600. PubMed ID: 31863948
[TBL] [Abstract][Full Text] [Related]
19. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
Bosiers M; Setacci C; De Donato G; Torsello G; Silveira PG; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Teβarek J; Giaquinta A; Wauters J
J Endovasc Ther; 2020 Apr; 27(2):287-295. PubMed ID: 31997715
[No Abstract] [Full Text] [Related]
20. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
Mwipatayi BP; Perera K; Daneshmand A; Daniel R; Wong J; Thomas SD; Burrows SA
Vascular; 2018 Feb; 26(1):3-11. PubMed ID: 28436316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
